Injection therapy Wainua offers ‘ray of hope’ for hATTR-PN patients

The injection therapy Wainua (eplontersen) “offers a vital ray of hope” for people living with hereditary transthyretin amyloidosis with polyneuropathy (hATTR-PN), an international team of scientists wrote in a review paper.

Available data suggest that Wainua, the most recently approved hATTR-PN therapy, “keeps patients with [hATTR-PN] in good health and offers them a better quality of life,” the scientists wrote.